Other research analysts also recently issued research reports about the company. Piper Jaffray Companies upped their price objective on argenx from $161.00 to $182.00 and gave the stock an overweight rating in a report on Thursday, May 23rd. Robert W. Baird began coverage on argenx in a report on Thursday, June 27th. They set an outperform rating and a $170.00 price objective on the stock. Zacks Investment Research downgraded argenx from a buy rating to a hold rating in a report on Tuesday, July 16th. Finally, Stifel Nicolaus reaffirmed a buy rating and set a $154.00 price objective on shares of argenx in a report on Thursday. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average price target of $152.27.
NASDAQ:ARGX traded down $1.97 during trading hours on Thursday, hitting $142.61. 125,354 shares of the stock were exchanged, compared to its average volume of 113,067. The company’s 50 day moving average is $140.44. argenx has a twelve month low of $63.81 and a twelve month high of $150.92. The firm has a market capitalization of $4.52 billion, a P/E ratio of -60.69 and a beta of 1.18.
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Featured Article: What does a dividend yield signify to investors?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.